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SUMMARY AND CONCLUSIONS OF THE FINDINGS IN THE
PRESENT THESIS
The present study examined the effect of the thiazolidione 
troglitazone and the influence of serum leptin on body composition in 
patients with non-insulin dependent diabetes meliitus. The study 
was designed as a double blind, randomised, placebo-controlled, 
parallel group trial, where subjects were allocated to receive either 
troglitazone or matching placebo. Sixteen males and seven females 
were recruited from the Diabetes Centre at Glasgow Royal Infirmary. 
All subjects were treated by diet alone or diet and sulphonylureas 
and had a fasting glucose between 8 and 16mmol/l. The commonly 
used anthropometric measurements as well as a standard 
underwater weighing method were employed to determine 
percentage body fat. A novel magnetic resonance imaging 
technique was used to calculate the volume of total abdominal and 
intra-abdominal fat. Serum leptin was analysed using a 
radioimmunoassay kit.
The results of the study indicate that troglitazone had no significant 
effect on body weight of total body fat. However troglitazone did 
significantly reduce intra-abdominal fat. Analysis of leptin with 
measures of adiposity showed that leptin correlated significantly with 
body fat by underwater weighing and body mass index, but
IV
:correlated weakly with intra-abdominal fat. These results suggest
'
that subcutaneous adipose tissue (which is the main site of body fat)
rather than intra-abdominal fat, is associated with leptin in
overweight subjects with NIDDM.
From the present study it is possible to suggest that:
1. Troglitazone significantly reduces intra-abdominal fat as 
measured by magnetic resonance imaging, but total body fat 
does not change significantly.
2. Troglitazone may preferentially increase insulin sensitivity and 
lipogenesis in tissues other than intra-abdominal fat, and the 
results would still be in keeping with minor (non significant) 
increases in other sites of adipose tissue.
4. Subcutaneous adipose tissue (the major body fat depot) rather 
than intra-abdominal fat, is associated with leptin in overweight 
diabetic subjects.
V
3. A single magnetic resonance imaging scan of the intra-abdominal 
fat area at the intervertébral disc between L2 and L3 vertebrae 
offers a cheaper, faster and safer method, with high prediction of
total-abdominal fat volumes.
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CHAPTER ONE
Introduction & Background
Literature review
1.1 Body Composition and fat distribution of patients with non-insuiin 
dependent diabetes
Historical perspectives
People with non-insulin dependent diabetes meliitus (NIDDM) have a 
distinctive body morphology, which was recognised by pioneering 
anthropologists such as Lister and Tanner (1955), who described the 
physique of NIDDM subjects as “roundness of the body contour, a tendency 
to obesity, smooth skin with fine hair, and short tapering limbs with small 
hands and feet.”
Body fat distribution in diabetic subjects was first examined by Jean Vague 
in the nineteen forties (Vague 1949). His pioneering work described diabetic 
men and women as having an “android” body shape, later described as an 
apple shape by scientists in the eighties. These patients tend to accumulate 
relatively more body fat around and particularly within the abdomen.
The associations of body fatness as indicated by body mass index, with 
morbidities and mortalities are well established from epidemiological data 
(Lew and Garfinkle, 1979). Body shape and fat distribution are reflected by 
waist to hip ratio (WHR). WHR has been shown to be a predictor of the 
incidence of diabetes meliitus in both adult men (Larson et at, 1984) and 
women (Ohlson, 1985) independently of body mass index. WHR has also 
shown to relate to the ratio of intra-abdominal to abdominal subcutaneous 
fat mass (Ashwell et al, 1985).
Recent advances
Waist circumference is marginally less good than WHR in identifying 
NIDDM in cross-sectional surveys (Han et al, 1998). However, recent 
evidence has shown that waist circumference alone is a better predictor of 
intra-abdominal fat than WHR (Han et al 1997a). Several longitudinal 
studies have shown that waist circumference is better than WHR in 
predicting the development of NIDDM in men over 13.5 years (Ohlson et 
al, 1985), and these findings were confirmed by other recent prospective 
studies by Carey et al (1996) and Wei et al (1997). These findings suggest 
that it is possible that large waist circumference predicts the development of 
NIDDM, whilst muscle loss leads to decreased hip circumference 
measurement when NIDDM develops.
Muscle atrophy may also be one of the key factors associated with NIDDM 
and related metabolic disturbances. This is supported by a study of Seidell et 
al (1997) showing that NIDDM subjects have both larger waist and smaller 
hips than expected for their given BMI.
NIDDM has a strong familial pattern suggesting an important genetic 
predisposition but it has also been suggested as a consequence of 
development failure of vital organs in early life, such as the pancreas and 
the liver. This has been considered as malnutrition at a critical stage of fetal 
development (Barker, 1994). It can be mimicked by gestational protein 
deficiency in animals (Hales & Barker, 1992).
Another more secure indicator of poor nutrition in early life is short stature 
(Floud et al 1990). Disproportionate limb length relative to body length, 
including high ratio of lower leg length to height, which may reflect 
interrupted growth (McCance, 1968), has been shown to associate with 
NIDDM (Han et al, 1997b). Whether the individual’s predisposition results 
from genetic factors or fetal insult, weight gain exceeding BMI 23kg/m^ is 
necessary for developing NIDDM (Chan et al, 1994).
1.2 Methods of measuring body composition
Total Body Fat
Many techniques have been developed for assessing body composition in 
human subjects. The conventional “gold standard” laboratory method is 
under-water weighing (UWW) which measures body density, a two 
compartment model from which fat and lean mass contents are estimated by 
employing standard figures for density of fat (0.9kg/L) and fat free mass 
(l.lkg/L) (Siri, 1961).
Other “standard” methods for measuring body composition include total 
body potassium, measuring intracellular water in which potassium 
concentration present is constant. This method detects the naturally 
occurring radioactive isotope fraction, which can be extrapolated to 
estimate total body potassium, and hence total body water (Brodie et al, 
1980). Deuterium (^ HgOg) labelled water can be ingested and its distribution 
gives a more distinct measure of total body water from which body fat can
be estimated from standard assumptions about water space (Schoeller et al, 
1989). The principles of these techniques are described by Brodie (1980), 
Garrow, (1983) and Shephard, (1991). Body water measurement together 
with methods such as dual X-ray absorptiometry (DEXA) to estimate body 
calcium and bone mass, allow the development of more complicated 3 and 4 
compartment models. These multicompartment models may have 
advantages in specific settings, but ultimately there is no independent “true” 
reference method.
Field methods o f assessing body composition 
The “standard” methods are rather complicated and expensive for everyday 
clinical use, therefore simple and cheaper anthropometric methods have 
been derived to estimate body composition and total body fat.
The skinfold technique uses skinfold calipers to measure subcutaneous fat at 
standard sites over the biceps, triceps, subscapular and suprailliac regions. 
The sum of these four skinfold thicknesses is used to predict body density 
measured by underwater weighing. Equations are available to relate 
skinfold thicknesses to percentage body fat (Durnin and Womersley, 1974).
Other simple anthropometric methods used to estimate body composition 
include the use of body mass index (Deuenberg et al, 1991) and more 
recently, equations employing waist circumference with or without tricep 
skinfold (Lean et al 1996) have been published, again these methods 
employed the use of regression equations derived from UWW.
All methods for assessing body composition introduce errors in subjects 
with unusual characteristics such as the elderly, extremely obese or with 
disease such as NIDDM and coronary heart disease (Lean et al 1996). The 
advantage of the waist method is that it takes account of variation in fat 
distribution and is thus preferred for subjects who may have altered fat 
distribution e.g. NIDDM patients (Lean et al, 1990)
1.3 Leptin and Body Fat
Leptin was identified in 1994 by Zhang et al (1994) as a product of a gene 
that is defective in an obese strain of ob/ob mice and soon after, its human 
homologue. Leptin is produced by adipocytes and their specific receptors 
are found in many tissues, including the hypothalamus in the brain, which is 
thought to be the most important feed back regulatory centre. Leptin’s main 
action is believed to be the signal for negative feed back control on appetite 
and energy expenditure.
Hypothalamus
t  Leptin
in fat tissue
t  energy expenditure 
Food intake 
i  Insulin 
4- Cortisol
?signal suppressing ob gene expression
Figure 1.1 Proposed mechanisms of the effects of leptin on physiological 
responses and its negative feedback loop
Administration of recombinant leptin to hormone-deficient ob/ob mice 
results in weight loss through reduced food intake and increased energy 
expenditure. It also causes diet induced weight loss in normal lean and 
obese mice (Considine, 1996). Giving exogenous leptin to animals results 
in weight loss but this effect has not been shown in humans. BMI correlates 
with plasma leptin but when leptin values for men and women with the 
same BMI are compared, women have higher concentrations and this can be 
related to a relatively larger fat mass in women (Considine, 1996).
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It is thought that one of leptin’s main actions is to inhibit the synthesis and 
release of the hypothamlamic neuropeptide Y, which has the effect of 
decreasing food intake, increasing thermogenesis and decreasing 
concentrations of corticosteroids and insulin in plasma.
Caro et al (1996) have hypothesised that if leptin concentrations of the 
cerebrospinal fluid can be equated to the hypothalamic interstitial leptin 
concentration, then it is possible to understand why obese people do not 
have the expected response to their endogenous hyperleptinaemia as they 
are leptin resistant. Thus, in humans the possibility of leptin resistance 
makes it less suitable as a treatment for obesity.
1.4 Biochemical properties and clinical potential of troglitazone
Troglitazone is a thiazoladinedione compound, which enhances the effect of 
insulin action on peripheral tissues and the liver, which improves 
hyperglycaemia, hyperinsulinaemia. Troglitazone treatment also decreases 
low density lipoprotein and triglycerides, while increases high density 
lipoproteins in subjects with NIDDM (Ghazzi et al 1997). It is well 
tolerated at all doses and is being evaluated as a treatment for NIDDM and 
impaired glucose tolerance.
Licences were granted in 1997 for clinical use of troglitazone in NIDDM 
subjects but if it increases insulin sensitivity then an increase in fat 
deposition might be expected, which could be an understandable result.
8
This would be of particular importance for long term health if the internal 
intra-abdominal fat was to be expanded.
In rodents troglitazone has been found to cause a marked increase in fat 
proliferation. A two year histopathologic evaluation in mice has 
demonstrated vascular tumours found mainly in the subcutis and often 
associated with adipocytes (Glaxo Wellcome Internal Report, 1997). These 
tumours were associated with plasma concentrations 13 to 18 times the 
human therapeutic steady state concentration. Doses associated with plasma 
concentrations three times the anticipated human therapeutic steady-state 
concentration did not cause vascular tumours above the control background. 
No such tumours were found in the rat and it was therefore proposed that 
the induction of tumours in the mice was related to their genetic 
predisposition. An unusual feature of the tumour was the fatty changes 
observed in adjacent adipocytes. No similar effects were observed in a 12 
months study of monkeys. Genetic toxicity tests were also found to be 
negative.
The mechanism of action of troglitazone has not yet been fully elucidated, 
however it appears to work by either mimicking or enhancing insulin action 
without any effects on p-cell insulin secretion (Fugiwara et al, 1988) with 
the end result of improving insulin-mediated glucose disposal and reducing 
hepatic glucose output, possibly involving an increase in clearance of 
circulating free fatty acids (Suter et al, 1992; Petrie and Donnelly, 1994).
Various in vitro and animal studies have demonstrated that troglitazone 
enhances insulin action at both the receptor and post receptor levels in both 
peripheral and hepatic tissues without the enhancement of insulin secretion 
(Fujiwara et al, 1988). Suter et al (1992) have demonstrated that 
troglitazone exerts its in vivo hypogiycaemic effect by improving peripheral 
insulin resistance and reducing hepatic glucose output, the circulating 
plasma insulin fell both in the fasting and postprandial states.
Antonucci et al (1997) have shown that troglitazone treatment for 12 weeks 
improved postglucose glycaemic response in patients with impaired glucose 
tolerance. Troglitazone has also been shown to activate the ligand sensitive 
transcription factor known as peroxisome proHferator activated receptor- 
gamma (PPAR-y). Activation of these receptors promotes adipocyte 
differentiation and regulation of a number of gene encoding proteins that 
regulate lipid metabolism, suggesting that the PPAR-y receptor may play a 
role in the adipogénie signalling cascade and lipid metabolism.
The action of troglitazone is in contrast to the effects of the traditional first- 
line hypogiycaemic drugs (sulphonylureas), which induce increased plasma 
insulin levels in certain NIDDM subjects by a direct effect on p cells (Oates 
et al, 1989). In a study of a small group of NIDDM subjects, troglitazone 
treatment was shown to substantially reduce peripheral insulin resistance, 
lowering the elevated rates of hepatic glucose production and decreasing the 
rates of insulin secretion.
10
In a study of meal tolerance test, the levels of free fatty acid and glucagon 
were shown to be significantly lower and remain reduced after treatment 
with troglitazone (Suter et al, 1992).
Evidence from the aforementioned studies suggest that troglitazone offers a 
new therapeutic option for the treatment of NIDDM. It is also possible that 
troglitazone could be combined with either sulfonylureas or small doses of 
exogenous insulin, which may provide an even more effective therapy for 
NIDDM patients. The possibility of enhancing insulin action in adipose 
tissue, which would increase fat deposition, might alternatively have a 
negative influence on diabetic control.
1.5 Research Questions of the present thesis
What is the effect of troglitazone on body fat and fat distribution in NIDDM 
patients?
What is the association of leptin with body fat and fat distribution in 
NIDDM patients?
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1.6 Hypotheses to be tested
1. To investigate the effect of troglitazone on body composition by
a. Underwater weighing - to quantify total fat
b. Subcutaneous skinfolds - to quantify subcutaneous fat
c. MRI “ to quantify intra-abdominal fat.
2. To examine the associations of leptin with body fat from different sites.
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1. If Troglitazone increases insulin sensitivity in adipose tissue it will also 
enhance lipogenesis and promote fat accumulation.
2. This effect may vary in different sites of adipose tissue.
3. Troglitazone might increase intra-abdominal fat, and thereby ultimately 
have a negative effect on diabetic control.
4. Leptin is associated differently with body fat from different depots.
1.7 Aims of the present thesis
 ... -■ * * . -1 ' ■ ' ‘r " ■_ I ■
CHAPTER TWO
METHODS
2.1 Study Design
This study was designed as a double blind, randomised, placebo-controlled, 
parallel group trial to determine the effect of troglitazone on body 
composition. Subjects were allocated randomly to receive either troglitazone 
or matching placebo. Randomisations were made in accordance with the 
code generated by Medical Data Sciences Clinical Pharmacology at Glaxo 
Wellcome. In addition to their usual treatment which was unchanged 
throughout the study, subjects in the treated group received three 200mg 
tablets of troglitazone (GR92132X) once daily and those in the placebo 
group received three identical placebo tablets (GR92132X) once daily for 12 
weeks.
2.2 Subjects
Sixteen male and seven female subjects with NIDDM were recruited from 
the Diabetes Centre at Glasgow Royal Infirmary. All subjects gave informed 
consent before entry into the study. Subjects were aged between 44 - 74 
years, treated by diet alone or diet plus sulphonylureas and were free from 
any active disease. Subjects selected for the present study had fasting blood 
glucose between 8 and 16mmol/l and body mass index (BMI) below 
40kg/m^, (the upper limit for MRI scanning).
Exclusion criteria included women of child bearing age, insulin treatment, 
cardiovascular disease, renal or hepatic disease, diabetic neuropathy, alcohol 
or substance abuse, participation in another clinical trial within the last three
14
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months, concurrent medications which have changed or commenced within
■;
three months of starting the study: metformin, insulin, hypolipidaemic drugs
■ :
or warfarin. Ethical approval was obtained from Glasgow Royal Infirmary 
Joint Ethics Committee and Health Care International Joint Ethical 
Committee.
2.3 Anthropometry
Height was measured using a fixed stadiometer (Castlemead, Herts, UK) to 
the nearest mm with the Frankfort plane horizontal. Measurements were 
made while subjects were wearing a swimming costume. Weight to the 
nearest 0.1kg was measured using regularly calibrated scales (Seca,
Germany).
Body circumferences were measured according to standard 
recommendations (WHO, 1995) using flexible steel tape (Holtain Ltd, 
Crymch, UK). Waist circumference was measured midway between the 
lowest rib margin and the lateral iliac crest. Subjects were asked not to tuck 
their stomach in while being measured. Maximum hip circumference was 
measured over the greater trochanters with the measuring tape held 
horizontal. Measurements were made while subjects stood with their feet 
about 20-30cm apart. Mid-upper arm circumference was measured at the 
midpoint between the acromion process and the olecranon. All 
measurements were taken twice and the mean was used for analysis.
15
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Subcutaneous skinfold thicknesses were measured at the sites of biceps, 
triceps, subscapular and supra-iliac using calipers (Holtain, Crymych, UK) to 
the nearest 0.2mm (Figure 1). All the skinfold thicknesses were measured in 
triplicate and the mean values were used in analysis. The skinfold equations 
have been derived to predict total body fat determined by underwater 
weighing (Durnin and Womersley, 1974).
2.4 Measuring total body density and body fat by underwater weighing
Body density was determined by underwater weighing (UWW) (Figure 2) as 
described by Lean et al (1996). A metal chair was suspended in a 
hydrotherapy pool, which was kept at a constant temperature of 36.5°C. The 
chair was attached to a strain gauge (Mecmesin Ltd Horsham, United 
Kingdom) with a 20kg range and sensitivity of 0.01kg. Subjects sat in the 
chair with the water up to their neck. A nose clip sealed their nose. Subjects 
were encouraged to clear their lungs by blowing out as much as they could 
and asked to gently lower their head underwater. The underwater weight 
was recorded by a pen recorder, which was calibrated with known weights 
before the experiment.
The residual lung volume was simultaneously measured with UWW by a 
three-breath-nitrogen technique modified from Womersley (1974). Four 
anaesthetic bags (Ohmeda PLC, Hatfield, United Kingdom) were filled with 
a known volume of 100% oxygen measured with a dry rolling seal 
spirometer (PK Morgan, Kent, United Kingdom).
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mFigure 1 -  Measuring s k in fo ld  t h ic k n e s s e s  using s k in fo ld  c a l ip e r s
Figure 2 - Measuring t o t a l  body d e n s i ty  by underwater w eigh ing
Approximately 3 litres for women and 4 litres for men (Wilmore et al, 1980). 
On raising their head, a 35ml mouthpiece connected to the anaesthetic bag 
was instantly inserted into the subject’s mouth. The subject then breathed 
deeply in and out of the bag three times.
After the last complete expiration, the bag was sealed and the gas mix 
obtained was immediately analysed for oxygen (Polarographic, PK Morgan, 
Kent, United Kingdom) and carbon dioxide (Infa-red, PK Morgan) contents. 
Nitrogen content of the gas mix was calculated from the difference in oxygen 
and carbon dioxide.
Residual lung volume was calculated as;
F x  A x  (F + 0.035/) 
80% -  NVo
Where V is the initial volume of 100% oxygen in the gas bag, 0.035 L is the 
volume of the dead space in the mouthpiece, with nitrogen content of 
alveolar air before the test assumed to be 80%. A correction factor (F) was 
included for standard temperature and pressure in dry conditions (STD);
_ 273 + Tb Patm -  PsF = ----------- X--------------273 4- Tg Patm -  Pa
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Subjects were allowed to practise the techniques for holding their breath, 
bending down and up, and breathing into the mouthpiece outside the pool. 
They also practised in the water to familiarise themselves with the pool 
environment. Four measurements were made for each subject, and the pool 
was allowed to become absolutely calm before starting.
Body density was calculated using the equation:
BD (W a-W w) / Dw -  RV
Where BD is body density (kg/1), Wa and Ww are weight of the subject in air 
and water respectively, Dw is the density of water at 36.5°C, and RV is 
residual lung volume.
Total body fat was calculated from body density using Siri’s equation 
(1961):
4 95BF%  = —  X 100% (B D -45)
Where percentage body fat (BF%) is in percentage of body weight.
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2.5 Measuring Abdominal Fat by Magnetic Resonance Imaging (MRI)
Measuring total abdominal fat by magnetic resonance imaging (MRI) 
(Figure 3) requires a series of consecutive images in order to calculate a 
volume. In this study, extra and intra-abdominal fat volumes were calculated 
using multiple MRI scans at the levels between LI and L5 vertebrae, The 
tissues of the abdomen were scanned using an MRI machine (General 
Electric corporation, Milauwkee, WI, USA) with a magnetic field strength of
1.5 Tesla. Ordinary spin echo sequences were used with a repetition time of 
350ms and echo time of 12ms for the abdominal measurement.
Four sagittal images of the trunk were scanned to find the vertebral column 
(Figure 4a). To obtain reproducible imaging volumes, the volumes of the 
abdomen were taken to extend from the bottom of the inferior plate of the 
LI to the bottom of the inferior plate of the L5 vertebra. Data were 
collected from as many continuous 20mm thick sections as could completely 
fit within this interval. This imaging volume approximately corresponds with 
the levels of the xiphisternum to the anterior iliac crest (Han et al, 1997 a & 
c). Transverse sections (eight in women and nine in men) were then analysed 
individually (Figure 4b).
A lump of lard (lipid) was placed next to a container of water in the MRI 
scanner to simulate lipid in adipose tissue (AT) and lean tissue. The scan 
was analysed to obtain the threshold value where only the fat in the lard 
could be imaged. Pilot tests determined the threshold value to be at 300
21
Figure 3 - Magnetic Resonance Imaging (MRI) fo r  scanning body t i s s u e s
!)
^ / c #  ^ rU:34iTfUZ/Tf \ecti/i vskMMOVF0V;42_^
3%-35/2#€K
Figure 4 - Abdominal f a t  images from Magnetic Resonance Imaging (MRI)
(arbitrary units) for every subject for subsequent calculations.
This method may be scanner specific and thus may not apply to other 
scanners.
Calculations of intra-abdominal and extra-abdominal adipose tissue (AT) 
were carried out after setting the appropriate threshold value (as determined 
from the lard at 300 units) that separates AT from lean tissues. The number 
of pixels for total abdominal AT was obtained from the regions of interest 
(ROI) by encircling the whole abdominal contents with an ovoid line (Figure 
4c). To obtain the number of pixels for intra-abdominal AT, the ovoid line 
was then positioned at the fascial plane to separate the intra-abdominal and 
extra-abdominal AT (Figure 4d). Total volume of abdominal AT (mm^) was 
obtained by summing the AT areas in eight (or nine in eight men) transverse 
scans obtained from each subject, and multiplied by 20 mm which was the 
slice thickness.
The factor 10“^ was used to convert the volume of AT in mm  ^ into litres, and 
then to volume of fat (kg) assuming AT contains 80% fat, 2% protein, 18% 
water with negligible minerals (Garrow, 1974). The average density of AT 
was assumed to be 0.9255kg/l (Siri, 1961), thus fat was converted from AT 
by a factor of 0.9255 x 80%. The difference between the total volumes of 
abdominal fat and intra-abdominal fat provides the total volume of extra­
abdominal fat.
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General equations 1-3 are for calculating coefficient of variation for 
repeated measurements.
Equation 1 x = —
Where x is overall mean
y ( a ~ b i yEquation 2 57) =
Where a is first observer and b is second observer, n is the number of 
subjects with repeated measurements and sd is the standard deviation of the 
differences in the repeated measurements.
SDEquation 3 C V  = -=r- x 100%
X
Where the CV is the coefficient of variation.
Calculation of coefficient of variation for repeated intra-abdominal fat 
by 2 different obseiwers using general equations above and data from 
table 2.1.
X = 156645
ï.:îi
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It  (156169-157122ÿ
57) = 1394.3
1394 3 CF = J_ZZ_xlOO% 156645
CF= 0.89% 
2.6 Blood pressures and Heart rate
Subjects rested in supine position for at least 10 minutes on a couch in a 
thermoneutral environment (24°C). Systolic blood pressure (SBP) was 
measured as the first Korotkoff sound and diastolic (DBP) as the fifth 
Korotkoff sound, using a standard sphygmomanometer. Mean arterial blood 
pressure was calculated as 1/3 (SBP - DBP) + DBP (Vander et al, 1990). 
Heart rate was taken at the brachial or radial artery for one minute.
2.7 Biochemical Measurements
2.7.1 Blood Sampling
Venesection was performed to collect fasting blood samples at week 0 
(baseline) and at week 12 (follow-up). Serum for measurement was collected 
by centrifugation of clotted blood at 3000g for 20 minutes at room 
temperature. Aliquots were pipetted into glass tubes, capped and stored at 
-70"C for later analysis.
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2.7.2 Leptin Analysis
Leptin was analysed using a radioimunoassay (RIA) kit from Linco 
Research, USA. Test tubes containing standards, quality controls and 
samples tubes were all prepared in duplicate, mixed with assay buffer, label, 
leptin antibody, precipitating reagent. The tubes were vortexed and 
incubated overnight at 4"C.
The next morning, all the tubes were set on ice and 1.0ml of cold 
precipitating reagent was added to all the tubes (except the totals) and vortex 
again and incubated for 20 minutes at 4°C and centrifuged for 30 minutes at 
2600rpm at 4®C to create a firm pellet. The supernatant was aspirated 
immediately leaving the pellet at the bottom of the tube, which was then 
counted using a gamma counter. A full account of the RIA kit procedure 
can be found in Appendix One.
2.8 Statistical Analysis
Statistical methods used to analyse the data in the present thesis were:
1. Linear regression analysis were used to determine the correlations 
between baseline variables e.g correlation between leptin (dependent) and 
body fat (independent).
2. Partial correlations were used to adjust for confounding factors e.g. 
correlations between leptin and body fat, with adjustments for gender and 
age.
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3. Independent t-tests were used to detect the differences between 2 
independent groups e.g. comparing the differences in intra-abdominal 
changes between the two study groups (treatment and placebo) from 
baseline to follow-up.
4. Paired t-tests were used to determine changes within each study group 
e.g. comparing the changes from baseline to follow-up in total body fat in 
each of the study groups.
Power calculations to determine the number o f subjects recruited 
With a view to use for the treatment of Type 2 diabetes or glucose 
intolerance, the present study was designed to have power to exclude an 
effect of 1.4% on percentage body fat which equated to an approximate 1kg 
effect on body weight in 12 weeks (90% power at p<0.05). (Bland, 1993).
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CHAPTER THREE
BASELINE RELATIONSHIPS
BETWEEN INDICES OF
ADIPOSITY AND LEPTIN
Part o f this chapter has been submitted as fu ll paper for publication in a peer- 
reviewedjournal as:
Kelly IE Han TS, Walsh K, Lean MEJ. Relationships between serum leptin 
and body fat compartments in non-insulin dependent diabetes.
Part o f this chapter has been presented at the European Congress o f Obesity 
(Dublin, 1997) and published as an abstract:
Kelly IE Han TS, Wallace AM, Walsh K, Lean MEJ. Body composition and 
leptin in non-insulin dependent diabetes. International Journal o f Obesity 1997 
Vol 21 (supplement 2) :S98.
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3.1 RESULTS
Table 3.4.1 shows the characteristics of 16 men and 7 women at baseline.
h o d  -k a rd sn ^  -to be.
Compared to men, the women older, lighter, shorter, but they had a higher 
BMI, waist circumference, higher waist to hip ratio, more extra-abdominal and 
total body fat, higher concentration of serum leptin and less intra- abdominal fat.
Table 3.4.2 shows the correlation coefficients between serum leptin and indices 
of adiposity, with and without adjustments for sex and age. For all degree of 
adjustments, serum leptin correlated significantly with all indices of adiposity, 
except intra-abdominal fat. After adjustment for sex and age, intra-abdominal 
fat became significantly correlated with serum leptin while the significant 
associations with extra-abdominal fat and subcutaneous skinfolds were lost.
The relationships between serum leptin and intra-abdominal fat (Figure 3.5.1) 
and waist circumference (Figure 3.5.4) appear to be sex specific, whereas the 
relationship with total extra-abdominal fat showed no sex difference (Figure 
3.5.2). Figure 3.5.3 shows that serum leptin correlated significantly to total 
body fat in men but there was no significant relationship in the women.
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3.2 Discussion
Previous studies have related circulating leptin to body fat using derived 
measurements such as skinfolds or bioelectrical impedance (BIA). The present 
study used standard method to determine total body fat by UWW (the gold 
standard) and a novel application of MRI scanning techniques to quantify 
abdominal fat compartments by direct measurements. These measures of 
adiposity were related to serum leptin in men and women with NIDDM. It was 
shown that serum leptin correlated weakly with intra-abdominal fat and more 
strongly with other indices of body fatness, including total body fat by 
underwater weighing and anthropometric measurements particularly BMI and 
waist circumference.
3.3 Conclusions
Our results suggest that subcutaneous adipose tissue, which is the main site of 
adipose tissue rather than intra-abdominal fat, is associated with leptin in 
overweight NIDDM subjects. These findings have an important health 
implication. It seems possible to conclude from our data that “leptin resistance” 
in NIDDM may be most marked in those with an expanded subcutaneous fat 
mass - i.e. not particularly in those with a more central fat distribution, which is 
a characteristic of NIDDM.
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If “leptin resistance” is important in the aetiology of obesity as has been 
suggested (Caro et al, 1996), then this conclusion would indicate no special role 
for leptin deficiency in patients who have or who develop NIDDM. 
Furthermore, treatment with exogenous leptin, if it is successful in overcoming 
insulin resistance and inducing weight loss, might therefore be expected to have 
its major effect on subcutaneous fat.
Our findings of sex specific relationships between serum leptin concentration 
with waist circumference are similar to previous results found by Zimmet et al 
(1996). Leptin treatment might thus have a lesser impact on diabetes control 
and related atherogenic factors than a treatment which reduces intra-abdominal 
fat. To test these new hypotheses which emerge from the present thesis, future 
research will require a similar study of non diabetic subjects, and detailed 
measurements of fat compartments during leptin treatment.
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Table 3.4.1 Subject characteristics
Men (n=16) Women (n=7)
Mean SD Mean SD
Age (years) 56.2 6.3 62.3 9.1
Weight (kg) 81.8 11.7 77.6 11.5
Height (m) 1.71 0.07 1.57 0.04
Body mass index (kg/m^) 27.9 3.0 31.6 4.7
Waist (cm) 100.3 9.9 107.1 9.0
Waist to hip ratio 1.02 0.10 1.07 0.08
Extra-abdominal fat by MRI (kg) 1.56 0.38 3.53 0.67
Intra-abdominal fat by MRI (kg) 3.16 0.64 2.52 0.63
Percentage body fat by UWW 31.0 5.0 44.5 6.0
Leptin (ng/ml) 6.92 3.76 21.7 8.88
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Table 3.4.2 Baseline relationships between indices of adiposity and leptin
Unadjustedf Sex adjusted^ Sex and Age 
adjusted^
BMI 0.707*** 0.645** 0.632*»
WHR 0.448* 0.446* 0.439*
Waist 0.645** 0.665** 0.668**
Sum of 4 skinfolds 0.650** 0.431* 0.425
Percentage body fat by UWW 0.782*** 0.473* 0.661**
Extra-abdominal fat by MRI 0.816*** 0.462* 0.398
Intra-abdominal fat by MRI 0.385 0.421 0.439*
*** p<0.001, **p<0.01, p<0,05. 
t  Bivariate correlations 
X Partial correlations
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CHAPTER FOUR
EFFECT OF TROGLITAZONE ON
BODY COMPOSITION,
PHYSIOLOGICAL AND
BIOCHEMICAL MEASURES
Part o f this paper was accepted by the British Diabetic Association for oral 
presentation and published as an abstract:
Kelly IE Han TS, Walsh K, Lean MEJ. Effects of troglitazone on intra­
abdominal fat in NIDDM patients. Diabetic Medicine 1997;14 (suppl 4):S21
Part o f this chapter has been submitted as a full paper for publication in a 
peer-reviewed journal as:
Kelly IE. Han TS, Walsh K, Lean MEJ. The effect of troglitazone on body 
composition in patients with type 2 diabetes.
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4.1 Results
Table 4.4.1 shows the characteristics of 12 subjects who were treated with 
trogiitazone and 10 subjects on placebo. There were no significant differences 
between the trogiitazone treated and the placebo treated groups at baseline or at 
follow-up.
Table 4.4.2 shows the changes in body composition within treatment groups 
and between treatment groups. There was a significant (p < 0.05)
decrease in intra-abdominal fat in subjects 
treated with trogiitazone for the 12 weeks. There were no significant changes in 
all measures of body composition in subjects who were treated with placebo. 
There were no differences between the two treatment groups in other measures 
of body composition (Figures 4.5,1 -  4.5.3) Subjects who were treated with 
trogiitazone lost significantly more (p < 0.05) intra-abdominal fat than the 
placebo treated group (Figure 4.5.4).
4.2 Discussion
Obesity and intra-abdominal fat accumulation are characteristics of NIDDM and 
the pre-diabetic state, and can be related to many of the metabolic abnormalities 
linked to diabetic complications and ill health.
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It is now well established that intra-abdominal fat is associated with a variety of
metabolic disorders including hyperlipidaemia, hypertension and diabetes
(Bjorntorp et al, 1991), and that a decrease in intra-abdominal fat leads to
decreases in total cholesterol, triglycerides, glucose, insulin and increases high
density lipoproteins (Lemieux et al, 1996). The present study was not designed
.to have power to evaluate the effect of trogiitazone on metabolic variables which 
have been demonstrated elsewhere (Ghazzi et al, 1997). However, the present 
study showed that after 12 weeks of trogiitazone treated subjects lost 
significantly more intra-abdominal fat than those who were on placebo. There 
were no differences between the two treatment groups for the changes in other 
measures of body mass and fatness.
In vitro and animal studies indicate that trogiitazone works by mimicking or 
enhancing insulin action at both receptor and post-receptor levels, in both 
peripheral and hepatic tissues, without any effect on pancreaticP-cell secretion 
(Fugiwara et al,, 1988). Trogiitazone thus works in contrast to the effects of 
certain commonly used hypoglycaemic drugs, which induce increased plasma 
insulin levels in certain Type 2 diabetic subjects (Oates et al, 1989). Increased 
insulin, or insulin sensitivity, enhances lipogenesis, and causes weight gain.
Ï
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.The gain in total body fat observed in animal studies may be due to activation of 
the ligand sensitive transcription factor known as the PPARy. Activation of 
these receptors promotes adipocyte differentiation and regulation of a number of 
gene encoding proteins that regulate lipid metabolism which suggests that the 
PPAR-y receptor may play a role in the adipogénie signalling cascade and lipid 
metabolism.
The decrease in intra-abdominal fat mass with trogiitazone is reassuring as this 
effect probably has positive health implications such as inducing a favourable fat 
distribution towards a more peripheral fat deposition (more pear shaped).
The present study employed standard and highly reproducible methods for
measuring body composition which included the gold standard UWW (Lean et
..al, 1996) to determine total body fat (repeatability <1%) and MRI to determine 
abdominal fat compartments. We have developed a novel method for 
calculating intra-abdominal and extra-abdominal fat (Han, Kelly, Lean, 1997) by 
taking advantage of the natural circular separation of intra-abdominal and extra­
abdominal fat by the fascial plane (Figure 3d). We used ovoid lines to 
determine the regions of interest (ROI) in these abdominal fat compartments, 
and found this method to be highly reproducible with a coefficient of variation 
for repeated measurements by two different observers of 0.89% (Table 2.1).
Why intra-abdominal fat mass falls while total body fat is maintained cannot be 
answered directly by the present study, but clearly the effect of trogiitazone on 
insulin sensitivity is less marked in the intra-abdominal fat. Evidence from the 
aforementioned studies suggest that trogiitazone offers a new therapeutic option 
for the treatment of NIDDM. It is possible that trogiitazone could be combined 
with either sulfonylureas or small doses of exogenous insulin, which may provide 
an even more effective therapy for NIDDM patients.
4.3 Conclusions
Total body fat and extra-abdominal fat from MRI measurements were unaltered 
and there was no change in total body fat measured by UWW. Non-insulin 
dependent diabetics treated with trogiitazone have a significant reduction in their 
intra-abdominal fat, which suggests that, as well as an insulin sensitising agent, 
trogiitazone might thus have health benefits related to other metabolic disorders 
by inducing a more favourable body fat distribution.
Trogiitazone increases insulin sensitivity at a whole body level, but does not 
increase total body fat because intra-abdominal fat is reduced. This suggests 
that trogiitazone increases insulin sensitivity in tissues other than intra-abdominal 
fat.
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Table 4.4.1. Characteristics of 11 subjects who were treated with trogiitazone
and 10 subjects on placebo
Trogiitazone (« = 11) Placebo (« = 10)
Mean SD Range Mean SD Range Pt
Baseline
Age (yrs) 58.0 8.6 44.1-68.7 58.6 7.50 48.4-74.1 0.78
Weight (kg) 78.9 11.2 61.7-102.0 82.1 12.2 61.8-107.2 0.88
Height (m) 1.66 0.09 1.49-1.78 1.69 ff09 1.59-1.85 0.54
BMI (kg/m') 2K7 3.9 22.9-37.1 28.6 3.76 24.0-35.6 0.71
Waist (cm) 100.1 10.3 82.1-122.5 102.7 9.1 90.6-116.5 0.79
Waist to hip ratio 1.03 0.12 0.90-1.36 1.02 0.06 0.93-1.12 0.82
Total Body fat (%) 34.5 7.1 25.6-45.1 33.4 9.2 23.2-54.4 0.89
Total Body fat (kg) 27A 7.3 15.8-38.1 28 6 102 19.4-48.7 0.78
Extra-abdominal fat (kg) 2.11 1.0 1.00-4.10 2.00 0.91 1.00-4.09 0.50
Intra-abdominal fat (kg) Z36 0.51 1.71-3.01 2.41 0.60 1.64-3.44 0.82
Follow-up data
Weight (kg) 79.6 11.4 62.5-103.5 82.3 12.2 61.6-107.5 0.60
BMI (kg/m') 29.0 4.13 23.2-38.11 28.74 3.78 24.1-35.19 0.89
Waist (cm) 102.2 10.2 83.5-124.5 102.6 11.1 87.8-121.2 0.93
WHR 0.94 0.15 0.49-1.03 0.99 0.05 0.89-1.05 0.33
Total Body fat (%) 35.5 7.31 25.9-45.2 32.9 9.71 23.3-55.5 0.51
Total Body fat (kg) 2R5 8.0 16.5-39.07 28.23 10.5 19.1-49.03 0.95
Extra-abdominal fat (kg) 2.03 1.05 0.45-3.82 1.84 0.90 1.04-3.84 0.66
Intra-abdominal fat (kg) 1.90 0.73 0.19-2.78 2.36 0.73 1.42-3.43 ffl6
f Independent t-tests for the differences in characteristics between groups.
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4.5 Effect of thiazolidinedione trogiitazone on body composition
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CHAFER FIVE
GENERAL DISCUSSION AND
CONCLUSIONS OF THE
PRESENT THESIS
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GENERAL DISUSSION
The results of the study indicate that trogiitazone had no significant effect on 
body weight or total body fat. However trogiitazone did significantly reduce 
intra-abdominal fat. This could be because trogiitazone induced increased 
insulin sensitivity in tissues other than intra-abdominal fat, as total fat was not 
significantly increased. This study in the present thesis is unique in that it used 
the gold standard method of underwater weighing to determine total body fat, 
and a novel technique to measure abdominal fat compartments from MRI was 
developed. In the therapeutic situation the availability of MRI would be limited 
as most MRI machines are heavily used for diagnostic purposes. It became clear 
from the MRI analysis that a single scan at the area of the intervertébral disc 
between L2 and L3 offers a cheaper, faster and safer method with a high 
prediction of total abdominal fat volumes. This unique single scan could prove 
very useful as a research tool in future studies. This fast, safe and non-invasive 
technique would enable large numbers of subjects to be studied, providing a high 
prediction of their total abdominal fat mass.
The nocturnal rise in leptin has been well documented (Sinha et al 1996).
During the present study leptin analyses was performed in subjects following an 
overnight fast. This consistent approach has minimised the variability associated 
with leptin measurements made throughout the day. The leptin analysis showed 
that leptin correlated to body fat by underwater weighing and body mass index.
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It is interesting that leptin only correlated weakly with intra-abdominal fat, which 
suggests that subcutaneous adipose tissue, which is the main site of adipose 
tissue, rather than intra-abdominal fat is associated with leptin in overweight 
NIDDM subjects.
This finding is supported Montague et al (1997) who have shown that mRNA 
appears to be expressed predominately by subcutaneous adipocytes, particularly 
in women.
These findings have important health implications as it seems possible to 
conclude from our data that “leptin resistance” in NIDDM may be most marked 
in those with an expanded subcutaneous fat mass i.e. not those with a more 
central fat distribution -  which is a characteristic of NIDDM.
If leptin resistance is important in the aetiology of obesity as it has been 
suggested, then this conclusion would indicate no special role for leptin 
deficiency in patients who have or who develop NIDDM. It is also possible that 
treatment with exogenous leptin, if it is successful in overcoming insulin 
resistance and inducing weight loss, might therefore be expected to have a major 
effect on subcutaneous fat.
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OVERALL CONCLUSIONS
L e p t i n
1. There is a sex specific relationship between waist and serum leptin
2. Serum leptin correlates weakly with intra-abdominal fat and more strongly 
with other indices of body fatness, including underwater weighing and 
anthropometric measurements, particularly, BMI and waist circumference.
3. The major depot of body fat, subcutaneous adipose tissue, rather than intra­
abdominal fat is associated with leptin in overweight NIDDM subjects.
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Trogiitazone
Trogiitazone has no significant effect on body weight.
1. Total body fat was not significantly changed when measured using the gold 
standard of underwater weighing.
2. Trogiitazone significantly reduced intra-abdominal fat mass measured by 
novel MRI technique.
3. It can be suggested that trogiitazone increases insulin sensitivity in tissues 
other than intra-abdominal fat, as total body fat does not increase 
significantly.
Methodology
1. A single MRI scan of the intra-abdominal fat area at the intervertébral disc 
between L2 and L3 vertebrae offers a cheaper, faster and safer method, with 
high prediction of total intra-abdominal fat volumes measured by multiple 
cuts.
2. Intra abdominal fat can be measured with high precision and coefficient of 
variation 0.89% using a novel multiple cut MRI technique.
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FUTURE DIRECTIONS
Possible further steps following this research:
1. Repeat study with glucose intolerant subjects to investigate the effects of 
thiazolidinedione drug on body composition and metabolic improvements at 
an earlier stage in the disease
2. Further develop the use of MRI to investigate the long-term effects of 
thiazolidinedione drug on adipose tissue depots and skeletal muscle mass.
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